- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01962974
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) (REGAIN)
This is a Phase 3b, multicenter study of the efficacy of golimumab 2 mg/kg IV in subjects with active rheumatoid arthritis who are receiving methotrexate and have inadequate disease control (defined as an erythrocyte sedimentation rate [ESR]-based Disease Activity Score in 28 joints [DAS28] ≥ 3.2 and ≥ 4 swollen and ≥ 4 tender joints) despite current anti-TNFα therapy with infliximab 2 - 4 mg/kg every 4 weeks, 2 - 5 mg/kg every 5 weeks, 3 - 6 mg/kg every 6 weeks, 3 - 7mg/kg every 7 weeks, or 4 - 8 mg/kg every 8 weeks.
To be eligible for participation, subjects must have previously demonstrated initial and/or temporary improvement in disease signs and symptoms, who have since exhibited a diminished response despite continued treatment. It is estimated that 200 subjects will be enrolled in the study at approximately 85 global sites.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study employs an open-label "active switch" design that moves subjects from infliximab to golimumab 2 mg/kg IV. In general, subjects eligible for the study include men or women who are currently receiving infliximab in actual clinical practice who are at least 18 years of age with active rheumatoid arthritis, and have previously demonstrated initial and/or temporary improvement in disease signs and symptoms, but now exhibit a diminished response and inadequate disease control despite continued treatment. Subjects must have received infliximab in combination with methotrexate for a minimum of 9 months prior to the first screening visit.
The screening visit will occur sometime between Week -12 and Week -10. Consenting subjects who meet screening criteria will receive their final dose of infliximab at Week -8 as part of actual clinical practice. Golimumab IV treatment, which will be supplied by the sponsor, will be received at Weeks 0, 4, 12, 20, and 28. The primary endpoint is at Week 24, the final efficacy assessment is at Week 32, and a follow-up safety assessment by telephone is at Week 44. There will be a maximum of 36 weeks between the last infliximab infusion at Week -8 and the last infusion of golimumab at Week 28. The duration of study participation is expected to be a maximum of 56 weeks (including the Screening Period, 32 weeks of golimumab treatment and assessment, and a 12-week safety follow-up).
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Rimouski, Canada
-
-
British Columbia
-
Victoria, British Columbia, Canada
-
-
Newfoundland and Labrador
-
Saint-John'S, Newfoundland and Labrador, Canada
-
St. John'S, Newfoundland and Labrador, Canada
-
-
Ontario
-
Hamilton, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis
-
Huntsville, Alabama, États-Unis
-
-
Arizona
-
Peoria, Arizona, États-Unis
-
Phoenix, Arizona, États-Unis
-
-
Arkansas
-
Fort Smith, Arkansas, États-Unis
-
-
California
-
Fremont, California, États-Unis
-
Fullerton, California, États-Unis
-
Long Beach, California, États-Unis
-
Santa Maria, California, États-Unis
-
Thousand Oaks, California, États-Unis
-
Whittier, California, États-Unis
-
-
Connecticut
-
Bridgeport, Connecticut, États-Unis
-
-
Florida
-
Clearwater, Florida, États-Unis
-
Miami, Florida, États-Unis
-
Orlando, Florida, États-Unis
-
Sarasota, Florida, États-Unis
-
Tampa, Florida, États-Unis
-
-
Idaho
-
Coeur D'Alene, Idaho, États-Unis
-
-
Indiana
-
Indianapolis, Indiana, États-Unis
-
South Bend, Indiana, États-Unis
-
-
Minnesota
-
Eagan, Minnesota, États-Unis
-
Edina, Minnesota, États-Unis
-
-
Missouri
-
Saint Louis, Missouri, États-Unis
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis
-
-
New York
-
Orchard Park, New York, États-Unis
-
-
North Carolina
-
Asheville, North Carolina, États-Unis
-
Charlotte, North Carolina, États-Unis
-
Greensboro, North Carolina, États-Unis
-
Hickory, North Carolina, États-Unis
-
Wilmington, North Carolina, États-Unis
-
-
Ohio
-
Dayton, Ohio, États-Unis
-
-
Pennsylvania
-
Duncansville, Pennsylvania, États-Unis
-
Philadelphia, Pennsylvania, États-Unis
-
Pittsburgh, Pennsylvania, États-Unis
-
Wyomissing, Pennsylvania, États-Unis
-
-
South Carolina
-
Charleston, South Carolina, États-Unis
-
Columbia, South Carolina, États-Unis
-
Myrtle Beach, South Carolina, États-Unis
-
-
Tennessee
-
Hixson, Tennessee, États-Unis
-
Jakson, Tennessee, États-Unis
-
Nashville, Tennessee, États-Unis
-
-
Texas
-
Houston, Texas, États-Unis
-
Plano, Texas, États-Unis
-
San Antonio, Texas, États-Unis
-
-
Virginia
-
Arlington, Virginia, États-Unis
-
-
Washington
-
Spokane, Washington, États-Unis
-
-
Wisconsin
-
Glendale, Wisconsin, États-Unis
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Major Inclusion Criteria include (but not limited to):
- Have a diagnosis of Rheumatoid Arthritis (according to the revised 1987 criteria of the American Rheumatism Association).
- Treatment with infliximab and methotrexate for >= 9 months, (with stable doses of methotrexate over last 16 weeks of 7.5 mg/week to 25 mg/week) and (anti-TNFα therapy with infliximab 2 - 4 mg/kg every 4 weeks, 2 - 5 mg/kg every 5 weeks, 3 - 6 mg/kg every 6 weeks, 3 - 7mg/kg every 7 weeks, or 4 - 8 mg/kg every 8 weeks).
- Disease Activity Score 28 (DAS28) ≥ 3.2 based on Erythrocyte Sedimentation Rate (ESR) at Week -8 and Week 0.
- Swollen joint count (SJC) ≥ 4 and tender joint count (TJC) ≥ 4 at Week - 8 and at Week 0.
- Prior response confirmed by physician.
Major Exclusion Criteria include (but not limited to):
- Have a history of latent or active granulomatous infection, including histoplasmosis, or Have a history of latent or active granulomatous infection, including histoplasmosis, or coccidioidomycosis, prior to the first screening visit or during the Screening Period.
- Have had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening.
- Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis.
- Have previously received more than 1 of the currently approved subcutaneous (SC) administered anti-TNFα agents, etanercept, certolizumab pegol, golimumab, or adalimumab.
- Are pregnant, nursing, or planning a pregnancy or fathering a child within 6 months after receiving the last administration of the study agent.
- Weight less than 35 kg or greater than 110 kg (less than 77 pounds or greater than 242 pounds).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Golimumab 2 mg/kg IV
Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
|
Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 24
Délai: Week 24
|
The ACR 20 Response is defined as greater than or equal to (>=) 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=20 percent improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS; 0-10 millimeter [mm], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas.
The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and erythrocyte sedimentation rate (ESR).
|
Week 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Percentage of Participants Who Achieved an ACR 20 Response at Week 24 With Confirmed Presence of Antibodies to Infliximab
Délai: Week 24
|
The ACR 20 Response is defined as >= 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=20 percent improvement in 3 of following 5 assessments: patient's assessment of pain using VAS (010 millimeter [mm], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas.
The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and ESR.
|
Week 24
|
Percentage of Participants Who Acheived ACR 20 Response at Week 24 With Trough Infliximab Levels Below the Lower Limit of Quantification (LLOQ)
Délai: Week 24
|
The ACR 20 Response is defined as >= 20 percent improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=20 percent improvement in 3 of following 5 assessments: patient's assessment of pain using VAS (010 millimeter [mm], 0 mm=no pain and 10 mm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, participant's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas.
The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and ESR.
|
Week 24
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Maladies auto-immunes
- Maladies articulaires
- Maladies musculo-squelettiques
- Maladies rhumatismales
- Maladies du tissu conjonctif
- Arthrite
- Arthrite, rhumatoïde
- Effets physiologiques des médicaments
- Agents anti-inflammatoires
- Agents immunosuppresseurs
- Facteurs immunologiques
- Inhibiteurs du facteur de nécrose tumorale
- Golimumab
Autres numéros d'identification d'étude
- CR102117
- CNTO148ART3003 (Autre identifiant: Janssen Biotech, Inc.)
- 2013-001809-91 (Numéro EudraCT)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Golimumab 2 mg/kg IV
-
Healthgen Biotechnology Corp.RecrutementEmphysème secondaire à un AATD congénitalÉtats-Unis
-
Healthgen Biotechnology Corp.ComplétéAscite HépatiqueÉtats-Unis
-
Flame BiosciencesRetiréCancer de l'estomac | Tumeur solide | Cancer du pancréas
-
BioMarin PharmaceuticalRésiliéDystrophie musculaire de DuchenneBelgique, Pays-Bas, Italie, Suède
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH); Department of Health and Human ServicesComplétéInfections à VIHÉtats-Unis, Zimbabwe, Kenya, Afrique du Sud
-
International AIDS Vaccine InitiativeBeth Israel Deaconess Medical Center; Ragon Institute of MGH, MIT and Harvard et autres collaborateursComplété
-
Janssen-Cilag International NVComplété
-
BioMarin PharmaceuticalRésiliéDystrophie musculaire de DuchennePays-Bas, Belgique, Italie, Suède
-
Bristol-Myers SquibbComplétéMélanomeFrance, Canada, États-Unis, Allemagne, Australie, Fédération Russe, Espagne, Italie, Pays-Bas, Pologne, Danemark, Israël, Royaume-Uni
-
Rockefeller UniversityBrigham and Women's Hospital; Weill Medical College of Cornell University; University...ComplétéEn bonne santé | VIHÉtats-Unis, Allemagne